Date: November 16, 2026

Regulatory Disclosure Summary

Wanbury Limited has submitted a regulatory filing pursuant to Regulation 30 of SEBI LODR regarding the outcome of a US FDA inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility.

Inspection Details

  • Facility Location: Tanuku, Andhra Pradesh
  • Inspecting Authority: United States Food and Drug Administration (US FDA)
  • Inspection Period: July 13, 2026 to July 17, 2026
  • Initial Intimation Date: July 22, 2026
  • Classification Received: Official Action Indicated (OAI)

Business Impact Assessment

According to the company's current assessment, the OAI classification:

  • Will not have any impact on business continuity
  • Will not affect customer supplies of existing products from this facility

Company Commitment

Wanbury Limited states that it:

  • Remains committed to working closely with the US FDA
  • Will maintain the highest standards of quality, regulatory compliance and manufacturing practices across all facilities
  • Will enhance its compliance on an ongoing basis

Filing Details

  • Filed Through: Jitendra J. Gandhi, Company Secretary
  • Digital Signature Date: November 16, 2026 at 13:49:16 IST
  • Regulatory Reference: SEBI LODR Regulation 30